resistance, page-5

202020,
Your explanation appears spot-on.

We appear to be entering a new phase with Tamiflu resistance becoming increasingly widespread. At the same time there is evidence of increased virulence which combined with the capacity of Swine Flu to infect deep in the lungs (compared with seasonal flu) is of extreme international concern.

An exuberant immune response in otherwise healthy individuals leads to a "cytokine storm" and lung destruction. To date the numbers/percentages have been small but based on the recent developments in Europe and Brazil this may be about to change.

The efficacy of I/V Relenza needs to be aggressively promoted in advance of results from the belatedly announced clinical trial.

There is concurrently a need for GSK to further ramp up manufacturing capacity of the Relenza above that recently announced.

Time to act may be short.

Regards
Kangaroo1